Cases and Conversations™: Navigating the New Immunotherapy Era in Squamous Cell Anal Carcinoma

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Marwan Fakih, MD, Kristen Ciombor, MD, MSCI, and Van Karlyle Morris, MD, discuss the treatment of advanced squamous cell anal carcinoma in the immunotherapy era, with a focus on epidemiology, frontline treatment, and novel approaches to immunotherapy-refractory disease.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Interpret recent clinical trial data and guideline recommendation updates to inform individualized care planning and optimize therapeutic sequencing in SCAC
• Evaluate the safety and efficacy data of emerging immune checkpoint inhibitors in SCAC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Incyte Corporation.

Faculty:

Marwan Fakih, MD

Professor, Medical Oncology and Therapeutics Research
Judy and Bernard Briskin Distinguished Director in Clinical Research
Associate Director for Clinical Sciences
Medical Director, Briskin Center for Clinical Research
Division Head, GI Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Adagene, Bayer, BMS, Delcath Systems, Iterion Therapeutics, Janssen, Merck, Microbial Machines, Mirati, Revolution Medicines, Roche/Genentech, Summit, Taiho, Xilio; Grant/Research Funding: AgenusBio, Genentech/imCORE, Verastem

Kristen Ciombor, MD, MSCI

Associate Professor of Medicine, Division of Hematology and Oncology
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Agenus, ALX, BeiGene, BMS, Exact Sciences, Merck, Pfizer, Summit, Taiho, Tempus; Grant/Research Funding: Array, Biomea, BMS, Calithera, Genentech, Incyte, Merck, NuCana, Pfizer, Seagen, Syndax

Van Karlyle Morris, MD

Associate Professor, GI Medical Oncology
Section Chief, Colorectal Cancer
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, AmMax Bio, BMS, BioNTech, Exelixis, GSK, Incyte, Pfizer, Scandion Oncology; Grant/Research Funding: AmMax Bio, BioNTech, BMS, Merck, Pfizer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information about risk factors for SCAC, management of locoregional disease, special considerations for patients living with HIV, and managing challenging cases of treatment-refractory disease, go to https://www.gotoper.com/cc26squamous-activity.

Release Date

February 27, 2026

Expiration Date

February 27, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.